February 2011 Editor's Picks: Products from Alfa Laval and GE Healthcare - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

February 2011 Editor's Picks: Products from Alfa Laval and GE Healthcare

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

product Alfa Laval
Diaphragm valve provides long service life

Alfa Laval’s Unique Diaphragm Valve is designed for aseptic, ultrahygienic, and sterile processes. The valve’s actuator can be fitted with various automation and control units that feature a compact design and facilitate conversion of the control function. The actuator also permits users to adjust the spring pressure to protect the diaphragm against excessive stress. In addition, the manual valves incorporate adjustable overclosure protection. These features help to prolong the life of the diaphragm and increase uptime.

The T- and tank-outlet valves are available in block and forged versions. The forged version weighs approximately 60% less than conventional T- and tank-outlet valve bodies, according to the company. The valves’ light weight makes them quick to heat up during heat sterilization and minimizes the need for piping support of the system. Alfa Laval manufactures the valve with high-quality components, including valve bodies with low delta-ferrite content and diaphragms for continuous-steam applications.


productGE Healthcare
Chromatography media enable high throughput

GE Healthcare’s Capto SP ImpRes cation exchangers and Capto Q ImpRes anion exchangers are designed for final biopharmaceutical purification processes. The products are based on a rigid agarose matrix that enables high flow rates, thus increasing volume throughput and reducing processing times. The rigid matrix also allows personnel to use high bed heights and small column diameters that can reduce the equipment’s footprint. The products’ ability to run at high flow rates and high bed heights gives users flexibility in process design.

The media’s small bead size (~40 µm) helps users achieve high resolution. The SP and Q ligands are intended to ensure predictable performance and robust processing. The ligands also are compatible with common downstream-purification buffers and are identical to those in GE Healthcare’s other ion-exchange media. The high resolution is intended to provide high purity and high yields.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Equipment and Processing Report,
Click here